Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2006-8-23
pubmed:abstractText
In 87 patients with aplastic anemia who failed to respond to immunosuppressive treatment, we determined the minimal dose of total body irradiation (TBI) required when added to antithymocyte globulin (ATG, 30 mg/kg x 3) plus cyclophosphamide (CY, 50 mg/kg x 4) to achieve engraftment of unrelated donor marrow. TBI was started at 3 x 200 cGy, to be escalated or deescalated in steps of 200 cGy depending on graft failure or toxicity. Patients were aged 1.3 to 53.5 years (median, 18.6 years). The interval from diagnosis to transplantation was 3 to 328 months (median, 14.6 months). Donors were HLA-A, -B, -C, -DR, and -DQ identical for 62 patients, and nonidentical for 1 to 3 HLA loci at the antigen or allele level for 25. The dose-limiting toxicity was diffuse pulmonary injury. The optimum TBI dose was 1 x 200 cGy. Nine patients did not tolerate ATG and were prepared with CY + TBI. Graft failure occurred in 5% of patients. With a median follow-up of 7 years, 38 (61%) of 62 HLA-identical, and 10 (40%) of 25 HLA-nonidentical transplant recipients are surviving. The highest survival rate with HLA-identical transplants was observed at 200 cGy TBI. Thus, low-dose TBI + CY + ATG conditioning resulted in excellent outcome of unrelated transplants in patients with aplastic anemia who had received multiple transfusions.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-10334542, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-10465104, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-10556959, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-10561256, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-10705155, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-10750722, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-11091219, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-11215697, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-11349807, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-11369628, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-11698275, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-12149198, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-12791654, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-14656884, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-15304387, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-15570255, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-15640818, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-15846573, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-16205733, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-16635793, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-1887251, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-2059756, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-2405918, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-3049951, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-3535929, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-4153799, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-6367054, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-8193380, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-8377778, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-8429851, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-8534759, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-8547667, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-9005744, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-9057668, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-9339750, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-9521984, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-9704734, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-9743948, http://linkedlifedata.com/resource/pubmed/commentcorrection/16684959-9787194
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
108
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1485-91
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy.
pubmed:affiliation
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop D1-100, PO Box 19024, Seattle, WA 98109-1024, USA. jdeeg@fhcrc.org
More...